Mar 13, 2018 Launching our molecular biology product Distribution business.

Over the last few years, we were often requested by our customers and recommended by advisors, to start a distribution division to address the unmet needs of fellow Canadian academic and industrial bio-researchers, for cost-effective reagents, lab equipment and consumables in molecular biology. This is also to capitalize on our own extensive expertise in molecular biology research and molecular diagnostics development as well as reagent manufacturing ranging from research-use products, to cGMP and ISO certified In Vitro Diagnostics products.

As our commercialization plan for the IVD division is gaining momentum, our team has recently completed an extensive strategic assessment, planning and logistical preparation for this launch of the Distribution division.

The company is pleased to announce today the launch of our Distribution business. Our goal is to help researchers in Canada with comprehensive and quality molecular biology products we either source from our original manufacturers at low cost, or make in-house, such that they get these products equivalent in quality and performance to the brand-name products, at significantly lower prices (See "Products" on www.genebiosystems.com).

We hope that the IVD division and the Distribution division will leverage each other, to help us to better serve the customers.

About GeneBio Systems, Inc.TM: We, in collaboration with our corporate partner CustomBiologicsTM, have been utilizing the DASL RAPIDTM isothermal DNA amplification technology to develop several infectious disease tests. They include:

a) Salmonella typhimurium detection for food safety;

b) Clostridium difficile detection for hospital acquired infections;

c) HIV-1 RNA detection for rapid point of care testing for AIDS disease treatment and management in low and middle-income countries (LMICs)*;

d) Zika viral RNA detection for Zika-related illnesses in LMICs.

We found these prototype tests to have high sensitivities (detecting as low as around 10 copies per reaction), high degree of specificity and short detection time (under 1 hour).

We have also developed and validated a DASL-compatible reagent lyophilization technology in partnership with an ISO 13485 certified IVD manufacturer partner. With this lyophilization technology, our DASL test reagents can be configured in a kit format, and be shipped to our customers at room temperature, sparing the need of cold chain during shipping. (Cold chain shipping is to use dry ice or blue ice containers to chill reagents during transportation). This development significantly reduces the cost of shipping of our products, at the same time affording convenience to customers in managing inventories and use of test products in their laboratories.

As a recent development, in December, 2017, Zika viruses in human urine matrix from 500 to 50,000 copies per reaction were detected using our DASL RAPIDTM Zika Test within 1 hour from sample to result, on a hand-held portal fluorometer reader (low cost, battery-powered, bar-code reader ready, multiple channels). We are continuing to evaluate and adapt this reader for DASL RAPIDTM tests. The reader is manufactured by a large US-based company specialized in lab testing.

The DASL technology is already protected by an issued patent in Europe, and is patent-pending in the US, Canadian and Chinese markets.

We are continuing our assay development and currently seeking partners to help us accelerate the commercialization of these research-use-only (RUO) products into In Vitro Diagnostics (IVDs).

For more information on GeneBio Systems, Inc.TM, contact:

Michael Ling, PhD, CEO

GeneBio Systems, Inc.TM

www.genebiosystems.com

3357 Petrie Way,

Oakville, Ontario L6L 6V7

Email: info@genebiosystems.com

For more information on CustomBiologicsTM, please see:

http://custombiologics.com/contact-us/

115 Skyway Ave
Toronto, ON M9W 4Z4
Tel: 416-479-3773
Email: info@custombiologics.com

* WHO | Definition of regional groupings, www.who.int/healthinfo/global_burden_disease/definition_regions/en/

News distributed to: LinkedIn and www.genebiosystems.com March 13, 2018

-------------------------------------------------------------------------------------------------

November 27, 2015 GeneBio Systems, Inc.TM is presenting its finding from the HIV assay development project at an international conference.

"I am excited to be presenting at the 3rd International Conference on HIV/AIDS, STDs and STIs"

  • By Michael Ling. Published originally on November 27, 2015 @ https://www.linkedin.com/pulse/i-am-excited-presenting-3rd-international-conference-hivaids-ling/

Among other things at GeneBio Systems IncTM, we have focused efforts on developing a 30-60 min HIV-1 RNA detection assay for plasma samples. Our assay offers portability, a low cost profile, and high performance results that fill an unmet need in developing countries for rapid molecular detection of HIV (from early to late stage infection).

We have developed an early prototype version of a HIV-1 RNA assay that utilizing an optimized two-step process with reverse transcription and DASL RAPIDTM isothermal amplification. Using a simple heater and a visual detection method, our HIV-1 assay demonstrates utility and potential as a low cost assay without the requirement of extensive training and skilled technicians.

I will be at the 3rd International Conference on HIV/AIDs, STDs and STIs in Atlanta November 30th and December 1st to discuss our prototype kits, results and initiatives moving forwards.

If you are there please come by... we can discuss our DASL RAPIDTM Isothermal amplification technology and what we are doing at GeneBio Systems IncTM.

Michael Ling www.genebiosystems.com

Source: Linkedin. https://www.linkedin.com/pulse/i-am-excited-presenting-3rd-international-conference-hivaids-ling/

An instruction video for the research-use HIV assay can be found here: https://www.youtube.com/watch?v=ZIngxceV0o0

Updated Dec. 2, 2015: we successfully presented a talk at the 3rd International Conference on HIV/AIDS, STDs & STIs November 30-December 02, 2015 Hilton Atlanta Airport, Atlanta, USA, Omincs International. For more information, please see the link below:

https://www.omicsonline.org/speaker/michael-m-ling-genebio-systems-inc-canada/

We would like to acknowledge our partner CustomBiologicsTM. Without their partnership, this project would not have been possible. We thank INTERNATIONAL POINT OF CARE INC (iPOC) for their support during this project. We also thank Grand Challenge Canada for their financial support to this project.

For more information on CustomBiologics, please see:

http://custombiologics.com/contact-us/

115 Skyway Ave
Toronto, ON M9W 4Z4
Tel: 416-479-3773
Email: info@custombiologics.com

For more information on iPOC, please see:

INTERNATIONAL POINT OF CARE INC (iPOC)

135 The West Mall, Etobicoke, ON M9C 1C2

http://www.ipocdx.com/services/

For more information on Grand Challenge Canada and the Stars in Global HealthTM Round 5 program, please see

http://www.grandchallenges.ca/contact-us/

MaRS Centre, West Tower
661 University Avenue, Suite 1720
Toronto, ON M5G 1M1

-------------------------------------------------------------------------------------------------

May 2, 2015 We are excited to attend the MaRS HealthKick 2015

The GeneBio Systems team will be attending the two-day events at the MaRS, Toronto, Ontario, Canada. We are excited to see new friends and old friends in the investment and healthcare communities at this show! We will be providing information on GeneBio Systems, our DASL isothermal amplification technology and our DASL RAPIDTM line of rapid test products.

For more information on GeneBio Systems, Inc.TM

contact:

Michael Ling, PhD, CEO

GeneBio Systems, Inc.TM

www.genebiosystems.com

Email: info@genebiosystems.com

For more information on the MaRS ad MaRS HealthKick 2015 event, please see:

http://healthkick2015.meeting-mojo.com/

https://www.marsdd.com/

-------------------------------------------------------------------------------------------------

July 31, 2013 We have been selected to receive funding from Grand Challenges Canada.

Our project proposal was entitled A Rapid and Early HIV RNA Test and it was submitted to Grand Challenges CanadaTM Request for Proposals: Stars in Global HealthTM Round 5 Phase I. Today, we have been notified that our project was selected by Grand Challenges Canada. Grand Challenges Canada received many high-quality submissions and the selection process was very competitive, and its peer review was led by the Canadian Institutes of Health Research.

"Ninety-five percent of the more than 30 million people with HIV live in developing countries and major HIV tests in wide use only detect antibodies months after infection. Quantifying HIV in plasma or viral load can aid in diagnosing acute HIV infection, determining prognosis and disease progression and aiding therapeutic monitoring. With the Rapid and Early-detection HIV RNA Test project, GeneBio Systems IncTM. sought to develop a technology to detect HIV DNA or RNA in disease specimens. We are excited to begin working with our partners to start the development of the HIV RNA test as soon as possible", says Michael Ling, PhD, CEO, GeneBio Systems, InTM

For more information, contact:

Michael Ling, PhD, CEO

GeneBio Systems, Inc.TM

www.genebiosystems.com

Email: info@genebiosystems.com

For more information on Grand Challenge Canada and the Stars in Global HealthTM Round 5 program, please see

http://www.grandchallenges.ca/contact-us/

MaRS Centre, West Tower
661 University Avenue, Suite 1720
Toronto, ON M5G 1M1

-------------------------------------------------------------------------------------------------